Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Kinomatic Launches "Kinect" Unified Web Platform for AI-Driven Orthopaedic Surgical Planning: Kinomatic released Kinect, a modern web-based ecosystem that unifies 3D CT segmentation, AI-guided alignment planning, and concierge communication across any connected device to streamline surgical preparation for joint arthroplasty.
• Nanochon Achieves First Patient Implantation in Chondrograft™ First-in-Human Clinical Trial for Knee Cartilage Restoration: Nanochon announced the successful first surgical case in its clinical study evaluating Chondrograft™, a patented 3D-printed synthetic implant engineered to restore focal articular cartilage defects in the knee.
• Joseph Spine Institute Inaugurates Dedicated Regenerative Therapy Center for Adipose-Derived Biologics and PRP: Joseph Spine Institute launched a specialized regenerative center in Tampa providing autologous adipose cell and PRP therapies to treat degenerative disc and facet pathology without invasive fusion.
• Arthrex Obtains FDA 510(k) Clearance for Bioabsorbable PushLock® Suture Anchors: Arthrex, Inc. received 510(k) clearance (K262357) for its updated Bioabsorbable PushLock® line, advancing knotless fixation for shoulder labral repair and soft tissue reattachment.
• TriMed Secures FDA 510(k) Clearance for Large Compression Screws in Extremity Reconstruction: TriMed, Inc. earned 510(k) clearance (K262344) for its Large Compression Screw system, expanding fixation options for trauma osteotomies and hindfoot arthrodesis.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

Kinomatic — Launches "Kinect" Unified Web Platform Powering AI-Driven Orthopaedic Surgical Planning and Workflow

• Summary: Kinomatic officially launched Kinect, a cloud-based unified platform designed to serve as the connective intelligence layer uniting 3D imaging, AI-assisted surgical planning, communication feeds, and surgeon preferences across arthroplasty workflows. Developed from the ground up as an AI-ready web application accessible across any device, Kinect enables orthopaedic surgeons to review pre-operative segmentation, fine-tune alignment strategies, track patient milestones, and seamlessly communicate preferences with concierge surgical engineers.
• Key Details:
  • Device/System Name: Kinect Unified Platform
  • Status: Commercial Launch / Cloud Enterprise Availability
  • Clinical Significance: Consolidates fragmented pre-operative imaging, alignment preferences, and surgical concierge logistics into a cross-device web ecosystem, minimizing friction between surgical planning and intraoperative execution in total joint replacement.
• Original Source: Kinomatic Kinect Platform Launch — OrthoSpineNews

Joint Reconstruction & Cartilage Regeneration

Nanochon — Implants First Patient in Chondrograft™ First-in-Human Clinical Trial for Knee Chondral Defects

• Summary: Nanochon announced the successful surgical treatment of the first patient enrolled in its First-in-Human clinical feasibility study evaluating Chondrograft™, a patented 3D-printed synthetic cartilage implant designed for focal chondral defects of the knee. Performed by Principal Investigator Dr. Juan Osorio, the procedure initiates clinical validation of a biomimetic polymer-nanomaterial scaffold engineered to provide immediate mechanical load-bearing while fostering native hyaline-like cartilage and subchondral bone regeneration.
• Key Details:
  • Device/System Name: Chondrograft™ 3D-Printed Cartilage Implant
  • Status: First-in-Human Clinical Trial Initiation
  • Clinical Significance: Addresses the critical clinical gap between palliative arthroscopic debridement and total knee arthroplasty by providing an off-the-shelf, minimally invasive structural implant capable of immediate weight-bearing and regenerative tissue integration for active patients with focal articular lesions.
• Original Source: Nanochon Chondrograft™ First-in-Human Trial Debut — OrthoSpineNews

Spine & Orthobiologics

Joseph Spine Institute — Launches Regenerative Therapy Center Featuring Autologous Adipose-Derived Cell and PRP Protocols

• Summary: The nationally recognized Joseph Spine Institute in Tampa, Florida, announced the opening of its specialized Regenerative Therapy Center, introducing evidence-guided autologous adipose-derived cell therapies and high-concentration platelet-rich plasma (PRP) treatments for complex spinal disorders. Tailored for patients suffering from degenerative disc disease, facet joint arthropathy, and chronic back pain, the clinical initiative pairs point-of-care cellular harvesting with image-guided fluoroscopic and ultrasound precision delivery to explore biologic alternatives to invasive arthrodesis.
• Key Details:
  • Device/System Name: Autologous Adipose Cell & PRP Spine Protocols
  • Status: Clinical Service Launch / Dedicated Specialized Center
  • Clinical Significance: Delivers structured, point-of-care orthobiologic alternatives for discogenic and posterior column spinal pathology, offering motion-preserving options that may mitigate systemic opioid utilization and delay or prevent surgical spinal fusion.
• Original Source: Joseph Spine Regenerative Therapy Center Launch — OrthoSpineNews

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Medtronic INFUSE® Bone Graft for TLIF Receives CMS New Technology Add-on Payment (NTAP) Eligibility: Medtronic announced that CMS granted NTAP eligibility for INFUSE® Bone Graft in transforaminal lumbar interbody fusion (TLIF) procedures effective October 1, 2026, lowering hospital adoption barriers for recombinant bone morphogenetic protein in inpatient spine surgery.
• Stryker Debuts FDA-Authorized SportSuite Vision for Apple Vision Pro with Landmark Hip Arthroscopy Case: Stryker completed the first surgical procedure utilizing its FDA De Novo-authorized SportSuite Vision application on Apple Vision Pro at Duke Health, integrating live arthroscopic feeds, preoperative CT reconstructions, HipCheck, and HipMap data into an ergonomic spatial computing environment within the sterile field.
• ONWARD Medical Achieves First Implant in Landmark EIGER Feasibility Study for Spinal Cord Injury Mobility: ONWARD Medical announced the first human implant in its EIGER clinical feasibility study evaluating the investigational ARC-IM® targeted epidural neurostimulation system for restoring upright standing and functional walking in subacute and chronic spinal cord injury patients.
• Spineart SA Secures FDA 510(k) Clearance for BAGUERA® C Cervical Disc Surgical Instruments: Spineart SA obtained clearance (K262639) for its dedicated instrumentation suite facilitating precision positioning and keel preparation for cervical total disc arthroplasty.
• Corin Receives FDA 510(k) Clearance for the Icona Hip Stem: Corin, Ltd. secured 510(k) clearance (K261576) for the Icona Hip Stem, expanding its reconstructive hip arthroplasty franchise with advanced biomimetic stem geometry.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Biologics Reimbursement

Medtronic — INFUSE® Bone Graft for TLIF Receives Medicare New Technology Add-on Payment (NTAP) Designation

• Summary: Medtronic Cranial & Spinal Technologies announced that the Centers for Medicare and Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for INFUSE® Bone Graft when utilized in transforaminal lumbar interbody fusion (TLIF) procedures, effective October 1, 2026. The designation provides incremental Medicare Fee-For-Service inpatient reimbursement when procedure costs exceed standard Medicare Severity Diagnosis-Related Group (MS-DRG) thresholds. This reimbursement approval follows the landmark FDA Premarket Approval (PMA) of INFUSE® for one- and two-level TLIF procedures following Breakthrough Device Designation, establishing economic viability for widespread hospital adoption.
• Key Details:
  • Device/System Name: INFUSE® Bone Graft (recombinant human bone morphogenetic protein-2 / rhBMP-2 on absorbable collagen sponge)
  • Status: CMS NTAP Approval (Effective Oct 1, 2026) / FDA PMA Approved (P000058/S043)
  • Clinical Significance: Eliminates hospital economic disincentives for utilizing proven osteoinductive growth factor biologics in TLIF, promoting solid arthrodesis while avoiding donor-site morbidity from autologous iliac crest bone graft harvesting.
• Original Source: Medtronic INFUSE® NTAP Designation Announcement — OrthoSpineNews

Surgical Robotics, AI & Spatial Computing

Stryker — Debuts FDA-Authorized SportSuite Vision for Apple Vision Pro with First Hip Arthroscopy Case

• Summary: Stryker announced the successful completion of the first surgical case utilizing SportSuite Vision on Apple Vision Pro at Duke Health, performed by Dr. Chad Mather III. SportSuite Vision received FDA De Novo authorization as the first intraoperative surgical application engineered for Apple Vision Pro spatial computing headsets. The software aggregates live high-definition arthroscopic video streams, HipCheck 3D intraoperative navigation, HipMap pre-operative planning, and volumetric CT slices into an interactive, heads-up spatial canvas manipulated seamlessly within the sterile surgical field.
• Key Details:
  • Device/System Name: SportSuite Vision for Apple Vision Pro
  • Status: FDA De Novo Authorization (DEN240032) / First Commercial Human Case Completed
  • Clinical Significance: Consolidates disparate physical OR video monitors into a customized, ergonomic heads-up spatial display, minimizing surgeon neck strain, preserving sterile field focus, and enhancing navigational precision during joint preservation procedures.
• Original Source: Stryker SportSuite Vision Clinical Debut Announcement — OrthoSpineNews

Spinal Neuromodulation & Clinical Trials

ONWARD Medical — First Patient Implanted in Landmark EIGER Feasibility Study for Spinal Cord Injury Mobility

• Summary: ONWARD Medical N.V. announced the first patient implantation in its landmark EIGER clinical feasibility study, evaluating the investigational ARC-IM® neurostimulation platform for restoring standing and functional walking. Conducted at Lausanne University Hospital (CHUV) in Switzerland under an Innosuisse grant, the EIGER trial is the first mobility protocol to enroll both subacute spinal cord injury patients (less than 6 weeks post-injury) and individuals with chronic motor paralysis. The therapy applies targeted, biomimetic electrical pulses directly to the lumbosacral dorsal root entry zones to re-engage dormant locomotor circuits.
• Key Details:
  • Device/System Name: ARC-IM® Implantable Neurostimulation System
  • Status: Clinical Feasibility Trial Initiation (EIGER Study / Investigational Device)
  • Clinical Significance: Accelerates motor rehabilitation by delivering synchronized, closed-loop epidural electrical stimulation during early neuroplasticity windows, aiming to restore voluntary weight-bearing and ambulatory independence.
• Original Source: ONWARD Medical EIGER Study Press Release — GlobeNewswire / Yahoo Finance

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Stryker Signs Definitive Agreement to Acquire ZuriMED to Expand Shoulder & Sports Medicine Portfolio: Stryker announced a definitive agreement to acquire Zurich-based ZuriMED Technologies AG, adding the FDA 510(k)-cleared FiberLocker System to address suture pull-through and structural failure modes in rotator cuff repair.
• Enovis Enters $180M Binding Agreement to Acquire Surgical Robotics Pioneer eCential Robotics: Enovis Corporation submitted a binding offer to acquire eCential Robotics, integrating robotic automation and 3D navigation directly into its joint reconstruction and spine ecosystems.
• Cornerstone Robotics and Medtronic Forge Global Strategic Partnership: Cornerstone Robotics and Medtronic entered an international strategic agreement to expand global clinical access to advanced robotic-assisted surgical instrumentation.

DAILY ANNOUNCEMENTS BY CATEGORY

Corporate, M&A & Shoulder/Sports Medicine

Stryker — Signs Definitive Agreement to Acquire ZuriMED to Bolster Shoulder Offering

• Summary: Stryker Corporation announced it has signed a definitive agreement to acquire ZuriMED Technologies AG, a Swiss medtech innovator spun out of ETH Zurich. The acquisition brings ZuriMED's proprietary FiberLocker System into Stryker's sports medicine and shoulder portfolios. The FDA 510(k)-cleared system is an intraoperative soft-tissue augmentation patch and instrument system designed to prevent suture cut-through at the tendon-to-bone interface during rotator cuff repair, directly targeting one of the primary failure modes in shoulder reconstruction.
• Key Details:
  • Device/System Name: FiberLocker System (SpeedPatch PET & FiberLocker Instrument)
  • Status: Definitive Acquisition Agreement / FDA 510(k) Cleared (K241219)
  • Clinical Significance: Provides mechanical augmentation that significantly increases time-zero construct strength in rotator cuff repair, reducing suture pull-through and re-tear risk.
• Original Source: Stryker ZuriMED Acquisition Announcement — OrthoSpineNews

Surgical Robotics, AI & Navigation

Enovis — Enters Binding Offer to Acquire eCential Robotics for $180M

• Summary: Enovis Corporation (NYSE: ENOV) announced a binding offer to acquire Grenoble, France-based eCential Robotics for approximately $180 million. The transaction unites eCential's open-architecture surgical robotics and intraoperative 2D/3D imaging platform with Enovis's reconstructive hip, knee, and spine implant franchises. The acquisition establishes a European robotics center of excellence in Grenoble and broadens Enovis's smart enabling technology footprint in both hospital and ambulatory surgery center (ASC) operating rooms.
• Key Details:
  • Device/System Name: eCential Robotics Open Surgical Robotics & Navigation Platform
  • Status: Binding M&A Acquisition Agreement ($180M) / FDA 510(k) Cleared
  • Clinical Significance: Integrates intraoperative robotic guidance and real-time navigation across total joint and spinal fusions, minimizing surgical footprint and improving bone resection accuracy.
• Original Source: Enovis eCential Robotics Acquisition Notice — GlobeNewswire

Cornerstone Robotics & Medtronic — Form Strategic Partnership to Expand Global Access to Robotic Surgery

• Summary: Cornerstone Robotics announced a strategic partnership with Medtronic to expand international access to robotic-assisted surgery platforms. The alliance leverages Cornerstone's vertically integrated, in-house R&D capabilities alongside Medtronic's global clinical and commercial infrastructure, aiming to bridge international adoption barriers and accelerate the delivery of cost-effective robotic surgical technologies into high-volume procedural suites.
• Key Details:
  • Device/System Name: Cornerstone Robotics Surgical Platform
  • Status: Global Strategic Commercial Partnership
  • Clinical Significance: Expands global surgical access to robotic instrumentation, facilitating standardized minimally invasive surgical workflows across diverse healthcare systems.
• Original Source: Cornerstone Robotics & Medtronic Partnership — OrthoSpineNews

Spine & Navigation Systems

Spineart & eCential Robotics — Obtain FDA 510(k) Clearance for PERLA® TL Navigation Application

• Summary: Spineart and eCential Robotics announced FDA 510(k) clearance for the PERLA® TL application integrated with the eCential Op.n® robotic navigation platform. The clearance enables surgeons to navigate Spineart's PERLA® thoracolumbar pedicle screw system with real-time robotic guidance, streamlining screw trajectory planning and reducing cumulative radiation exposure during open and minimally invasive spine fusions.
• Key Details:
  • Device/System Name: PERLA® TL Navigation Application for eCential Op.n®
  • Status: FDA 510(k) Cleared
  • Clinical Significance: Combines low-profile thoracolumbar pedicle fixation with robotic trajectory tracking, enhancing pedicle screw placement precision in complex degenerative spine cases.
• Original Source: Spineart & eCential Regulatory Clearance Announcement

Biologics & Supply Chain Innovation

AlloPort — Commercial Launch of Neutral B2B Allograft Procurement Platform

• Summary: AlloPort officially launched its neutral digital procurement marketplace, purpose-built to connect AATB-accredited tissue banks directly with hospital and ASC surgical teams. By providing real-time visibility into available structural bone, tendon, and osteochondral allografts, the platform eliminates traditional distribution markups and accelerates tissue matching for reconstructive orthopaedic cases.
• Key Details:
  • Device/System Name: AlloPort Digital Allograft Procurement Network
  • Status: Commercial Launch (September 1, 2026)
  • Clinical Significance: Streamlines hospital inventory access to verified musculoskeletal allografts, reducing supply chain delays in complex revision and limb reconstruction procedures.
• Original Source: AlloPort Commercial Launch — Orthopedics This Week

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Remex Medical Receives FDA 510(k) Clearance for Remex Spine Surgery Navigation Platform: Remex Medical Corp. received FDA clearance for its Universal Instruments spine navigation system, providing open-architecture stereotaxic instrumentation across multi-vendor pedicle screw systems.
• Surgical Navigation Systems Market Accelerates at 14.4% CAGR Toward Outpatient Migration: Market intelligence reported by OrthoSpineNews projects robust growth in stereotaxic surgical navigation driven by expanding adoption in ambulatory surgery centers (ASCs).
• Globus Medical Integrates AI-Driven Care Management Following Higgs Boson Health Acquisition: Globus Medical is integrating Duke-incubated Higgs Boson Health's software with its ExcelsiusGPS® robotics suite to manage perioperative episodes of care.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

Remex Medical — FDA 510(k) Clearance Granted for Spine Surgery Navigation Universal Instruments

• Summary: Remex Medical Corp. obtained FDA 510(k) clearance (K262506) for its Remex Spine Surgery Navigation - Universal Instruments platform. Classified as an Orthopedic Stereotaxic Instrument (Product Code OLO), the system provides tracked universal navigation instruments compatible with multiple third-party pedicle screw systems and intraoperative imaging modalities, enabling precise trajectory guidance without proprietary implant locking.
• Key Details:
  • Device/System Name: Remex Spine Surgery Navigation - Universal Instruments
  • Status: FDA 510(k) Cleared (K262506)
  • Clinical Significance: Provides open-platform stereotaxic guidance, reducing hospital capital lock-in and improving pedicle screw placement accuracy during minimally invasive spine surgery.
• Original Source: FDA 510(k) Premarket Notification Database

OrthoSpineNews / Market Report — Surgical Navigation Systems Market Projected at 14.4% CAGR Through 2030

• Summary: A market intelligence report published by OrthoSpineNews details accelerating demand for orthopaedic and spine surgical navigation systems, projecting a 14.4% compound annual growth rate through 2030. Key growth drivers include the migration of total joint arthroplasty and spinal instrumentation into ambulatory surgery centers (ASCs), where lightweight optical and CT-free navigation platforms offer sub-millimeter precision without the high capital footprint of full robotic consoles.
• Key Details:
  • Device/System Name: Orthopaedic & Spine Surgical Navigation Platforms
  • Status: Industry Market Intelligence Report
  • Clinical Significance: Highlights expanding adoption of cost-effective, space-efficient stereotaxic guidance in outpatient total joint and spine procedures.
• Original Source: OrthoSpineNews Surgical Navigation Market Report

Corporate, M&A & Digital Health

Globus Medical — Completes Acquisition of Higgs Boson Health to Expand Digital Care Ecosystem

• Summary: Globus Medical, Inc. (NYSE: GMED) announced the acquisition of Higgs Boson Health, a Durham, NC-based digital health company incubated out of Duke University. The integration pairs Higgs Boson's AI-enabled patient engagement and perioperative navigation platform with Globus Medical's ExcelsiusGPS® surgical robotics and implant ecosystems, providing continuous digital care management across the full episode of surgical care.
• Key Details:
  • Device/System Name: Higgs Boson Digital Health Platform & ExcelsiusGPS® Ecosystem
  • Status: Strategic M&A Completed
  • Clinical Significance: Connects preoperative patient preparation and remote postoperative functional tracking directly with intraoperative surgical navigation data.
• Original Source: Globus Medical Acquisition Announcement — GlobeNewswire

Sports Medicine & Clinical AI

AMSSM & OpenEvidence — Exclusive Partnership to Co-Develop AI Sports Medicine Clinical Resources

• Summary: The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence announced a strategic partnership to co-develop dedicated AI-powered point-of-care clinical decision support tools and patient educational resources. The platform integrates AMSSM's clinical practice guidelines, position statements, and expert sports medicine publications directly into OpenEvidence's clinical AI search interface.
• Key Details:
  • Device/System Name: AMSSM / OpenEvidence Sports Medicine Clinical AI Platform
  • Status: Strategic Educational & Clinical AI Partnership
  • Clinical Significance: Equips sports medicine specialists and orthopaedic surgeons with rapid, evidence-grounded decision support for acute musculoskeletal injury management and return-to-sport clearance.
• Original Source: AMSSM & OpenEvidence Partnership Announcement — OrthoSpineNews

Spine & Sacro-Pelvic Reconstruction

Tenon Medical — Closes $3M Private Placement to Accelerate Catamaran® SI Joint Fusion Commercialization

• Summary: Tenon Medical, Inc. (NASDAQ: TNON) completed a $3.0 million private placement offering of common stock and warrants at an effective price of $5.02 per share. The proceeds will fund nationwide commercial distribution, surgeon education, and clinical evidence initiatives for the Catamaran® Sacroiliac (SI) Joint Fusion System.
• Key Details:
  • Device/System Name: Catamaran® SI Joint Fusion System
  • Status: Private Placement Financing ($3.0M)
  • Clinical Significance: Expands surgeon training and access for single-transfixion posterior-inferior sacroiliac joint stabilization in outpatient spine surgery.
• Original Source: Tenon Medical Private Placement Announcement — OrthoSpineNews

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Globus Medical Acquires Higgs Boson Health to Expand Digital Care and AI Platforms: Globus Medical acquired Duke-incubated digital health developer Higgs Boson Health to integrate AI-driven patient engagement, remote monitoring, and perioperative management into its musculoskeletal surgical ecosystem.
• AMSSM and OpenEvidence Partner to Deliver AI Clinical Decision Support in Sports Medicine: The American Medical Society for Sports Medicine (AMSSM) entered a collaboration with OpenEvidence to co-develop specialized AI point-of-care clinical resources for sports medicine physicians.
• Tenon Medical Prices $3M Private Placement to Accelerate Catamaran® SI Joint Fusion Commercialization: Tenon Medical secured $3.0 million in private equity financing to fund commercial distribution and clinical education for its Catamaran® SI Joint Fusion system.

DAILY ANNOUNCEMENTS BY CATEGORY

Corporate, M&A & Digital Health

Globus Medical — Acquires Higgs Boson Health to Drive AI-Powered Episode-of-Care Solutions

• Summary: Globus Medical, Inc. (NYSE: GMED) announced the acquisition of Higgs Boson Health, a Durham, NC-based digital health company incubated out of Duke University. The acquisition expands Globus Medical's digital health suite, combining Higgs Boson's AI-enabled patient engagement and care management software with Globus's ExcelsiusGPS® robotic navigation ecosystem to optimize clinical workflows from preoperative planning through post-operative recovery.
• Key Details:
  • Device/System Name: Higgs Boson Digital Care Platform & ExcelsiusGPS® Ecosystem
  • Status: Strategic M&A Completed
  • Clinical Significance: Connects intraoperative robotic surgical navigation with remote patient tracking and education, improving patient compliance and streamlining post-operative outcome reporting.
• Original Source: Globus Medical Acquisition Announcement — GlobeNewswire

Sports Medicine & Clinical AI

AMSSM & OpenEvidence — Strategic Partnership to Co-Develop AI Sports Medicine Clinical Decision Tools

• Summary: The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence announced an exclusive partnership to develop specialized AI-driven clinical resources for sports medicine clinicians and athletes. The collaboration incorporates AMSSM's clinical guidelines, position statements, and expert-authored sports medicine content into OpenEvidence's clinical decision support search platform.
• Key Details:
  • Device/System Name: AMSSM / OpenEvidence Sports Medicine Clinical AI Platform
  • Status: Strategic Educational & Clinical AI Partnership
  • Clinical Significance: Delivers rapid, evidence-grounded point-of-care guidance for clinicians evaluating acute musculoskeletal trauma, concussions, and return-to-play decisions.
• Original Source: AMSSM & OpenEvidence Partnership Announcement — OrthoSpineNews

Spine & Sacro-Pelvic Reconstruction

Tenon Medical — Announces Pricing of $3M Private Placement Offering for Catamaran® Expansion

• Summary: Tenon Medical, Inc. (NASDAQ: TNON) announced a securities purchase agreement for a $3.0 million private placement offering of common stock and accompanying warrants at an effective price of $5.02 per share. Net proceeds will fund nationwide commercial distribution, clinical trial evidence generation, and surgeon training for the Catamaran® Sacroiliac (SI) Joint Fusion System.
• Key Details:
  • Device/System Name: Catamaran® SI Joint Fusion System
  • Status: Private Placement Financing ($3.0M) / Commercial Expansion
  • Clinical Significance: Supports expanded surgeon access and training for single-transfixion posterior-inferior sacroiliac joint stabilization in outpatient and ASC settings.
• Original Source: Tenon Medical Private Placement Announcement — OrthoSpineNews

Spinal Elements — Commercial Launch of Overwatch® PCF Posterior Cervical Fixation System

• Summary: Spinal Elements announced the commercial launch of Overwatch® PCF, a posterior cervical fixation system engineered for complex cervical and occipito-cervico-thoracic reconstruction. The system features polyaxial screws offering 120 degrees of angulation, freely functioning low-profile tulips, and self-selecting set screws designed to simplify rod seating in crowded posterior cervical anatomy.
• Key Details:
  • Device/System Name: Overwatch® PCF Posterior Cervical Fixation System
  • Status: Commercial Launch / FDA 510(k) Cleared
  • Clinical Significance: Streamlines instrumentation and screw-rod assembly in multi-level posterior cervical fusions, reducing soft-tissue retraction strain and operative time.
• Original Source: Spinal Elements Overwatch PCF Launch — SPINEMarketGroup

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Avalanche Medical Awarded FDA Breakthrough Device Designation for SyCap Focal Knee Resurfacing Implant: MedTech biomaterials innovator Avalanche Medical received FDA Breakthrough Device Designation for SyCap, a non-degradable polymer resurfacing implant designed to treat focal knee osteochondral defects without joint sacrifice.
• Spineart & eCential Robotics Secure FDA 510(k) Clearance for PERLA® TL Robotic Application: Spineart and eCential Robotics obtained FDA 510(k) clearance for the PERLA® TL planning and navigation app, enabling robotic-assisted pedicle screw placement and instrumentation on the eCential open robotic platform.
• GMReis Obtains FDA Clearance for High-Strength STITCH Suture Platform: GMReis secured FDA 510(k) clearance for its STITCH surgical suture portfolio, delivering high-tensile UHMWPE constructs for sports medicine, rotator cuff, and soft-tissue reconstruction.

DAILY ANNOUNCEMENTS BY CATEGORY

Joint Preservation & Biomaterials

Avalanche Medical — Receives FDA Breakthrough Device Designation for SyCap Focal Knee Resurfacing Implant

• Summary: Avalanche Medical announced that the U.S. FDA has granted Breakthrough Device Designation for its SyCap knee resurfacing implant. Composed of a proprietary non-degradable synthetic polymer, SyCap is engineered to replace damaged focal articular cartilage and subchondral bone defects in the femoral condyle, providing immediate structural load-bearing capacity and a low-friction articulating surface against native tibial cartilage. The technology serves as a vital bridge between biologic cartilage repair and total/unicompartmental knee arthroplasty.
• Key Details:
  • Device/System Name: SyCap Non-Degradable Polymer Focal Knee Resurfacing Implant
  • Status: FDA Breakthrough Device Designation Granted
  • Clinical Significance: Offers an off-the-shelf, motion-preserving synthetic solution for severe focal chondral defects, relieving joint pain while delaying the need for partial or total knee replacement in active patients.
• Original Source: Avalanche Medical Breakthrough Device Release — ORTHOWORLD

Surgical Robotics, AI & Navigation

Spineart & eCential Robotics — FDA 510(k) Clearance for PERLA® TL Application on eCential Op'n Platform

• Summary: Spineart and eCential Robotics announced FDA 510(k) clearance for the PERLA® TL navigation and robotic software application. The software enables seamless preoperative planning and intraoperative execution of Spineart's PERLA® thoracolumbar pedicle screw system directly on eCential's open robotic navigation platform. The integrated workflow combines low-dose 2D/3D intraoperative imaging, real-time optical tracking, and robotic arm trajectory guidance.
• Key Details:
  • Device/System Name: PERLA® TL Software & eCential Op'n Robotic Navigation Platform
  • Status: FDA 510(k) Cleared
  • Clinical Significance: Enhances pedicle screw placement trajectory accuracy, reduces operative duration and intraoperative radiation exposure, and expands robotic versatility in complex thoracolumbar spine procedures.
• Original Source: Spineart & eCential FDA Clearance — OrthoSpineNews

Sports Medicine & Soft Tissue Reconstruction

GMReis — Receives FDA 510(k) Clearance for STITCH Non-Absorbable High-Strength Surgical Sutures

• Summary: GMReis secured FDA 510(k) clearance for its STITCH surgical suture portfolio in the United States. Manufactured from medical-grade ultra-high-molecular-weight polyethylene (UHMWPE), the suture line includes high-strength braided sutures and tubular sleeves designed for soft-tissue reattachment, sports medicine repairs, and integration with all-suture anchors and flexible orthopaedic fixation constructs.
• Key Details:
  • Device/System Name: STITCH Non-Absorbable Surgical Suture System
  • Status: FDA 510(k) Cleared / US Commercial Expansion
  • Clinical Significance: Delivers high tensile strength, knot security, and abrasion resistance for rotator cuff, glenoid labrum, and ligamentous soft-tissue reconstructions.
• Original Source: GMReis FDA Clearance Announcement — ORTHOWORLD

Clinical Evidence & Perioperative Medicine

Orthopedics This Week — GLP-1 Receptor Agonists and 90-Day Arthroplasty Outcomes

• Summary: Clinical research featured in Orthopedics This Week analyzed 90-day postoperative outcomes among diabetic and obese patients undergoing primary total hip and total knee arthroplasty while receiving GLP-1 receptor agonist therapy. While sustained weight reduction and metabolic control provide long-term joint health benefits, the investigation identified critical perioperative considerations regarding delayed gastric emptying during anesthesia induction, recommending clear multi-specialty withholding protocols prior to elective joint replacement.
• Key Details:
  • Device/System Name: Perioperative GLP-1 Clinical Protocol Guidelines
  • Status: Clinical Evidence Review
  • Clinical Significance: Informs preoperative patient optimization, minimizing pulmonary aspiration risks and gastrointestinal complications during elective arthroplasty.
• Original Source: GLP-1 Arthroplasty Clinical Review — Orthopedics This Week

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Spineart and eCential Robotics Secure FDA 510(k) Clearance for PERLA® TL Robotic Application: Spineart and eCential Robotics received FDA 510(k) clearance for the PERLA® TL application, integrating Spineart's thoracolumbar pedicle screw system directly with eCential's Op.n open robotic navigation platform.
• FDA Grants Breakthrough Device Designation for Avalanche Medical's SyCap™ Knee Resurfacing Implant: Avalanche Medical was granted FDA Breakthrough Device Designation for its SyCap™ non-degradable polymer implant, engineered for focal joint-preserving resurfacing of knee osteochondral defects.
• GMReis Obtains FDA 510(k) Clearance for STITCH High-Strength Orthopaedic Sutures: GMReis secured FDA clearance for its STITCH portfolio of ultra-high-molecular-weight polyethylene (UHMWPE) non-absorbable sutures and braided sleeves for sports medicine tendon and ligament reconstruction.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

Spineart & eCential Robotics — FDA 510(k) Clearance for PERLA® TL Application on Op.n Robotic Navigation System

• Summary: Spineart and eCential Robotics announced that the FDA has granted 510(k) clearance for the PERLA® TL software application. This milestone enables Spineart's PERLA® thoracolumbar pedicle screw portfolio to operate seamlessly with the eCential Op.n open navigation and robotic-assisted spine surgical platform. The integration delivers unified, real-time 3D navigation and robotic guidance for planning and executing pedicle screw placement in degenerative, deformity, and trauma thoracolumbar fusions.
• Key Details:
  • Device/System Name: PERLA® TL Application & eCential Op.n Robotic Navigation System
  • Status: FDA 510(k) Cleared (August 26, 2026)
  • Clinical Significance: Combines robotic trajectory accuracy with premium thoracolumbar instrumentation, reducing screw malpositioning risks, surgical revision rates, and intraoperative radiation exposure.
• Original Source: Spineart & eCential Robotics FDA Clearance Announcement — OrthoSpineNews

Joint Reconstruction & Cartilage Restoration

Avalanche Medical — FDA Breakthrough Device Designation for SyCap™ Focal Knee Resurfacing Implant

• Summary: Avalanche Medical announced that its SyCap™ non-degradable synthetic cartilage resurfacing implant has received Breakthrough Device Designation from the US FDA. Engineered from a proprietary biocompatible polymer designed to match the biphasic tribological and compressive properties of native articular cartilage, SyCap provides focal joint resurfacing for full-thickness femoral and trochlear osteochondral defects in patients too young or active for total knee arthroplasty.
• Key Details:
  • Device/System Name: SyCap™ Non-Degradable Focal Knee Resurfacing Implant
  • Status: FDA Breakthrough Device Designation (August 26, 2026)
  • Clinical Significance: Provides an off-the-shelf, load-bearing joint preservation option for symptomatic focal cartilage defects, delaying or eliminating the need for early knee arthroplasty.
• Original Source: Avalanche Medical Breakthrough Device Update — Orthoworld

Sports Medicine & Soft Tissue Reconstruction

GMReis — Receives FDA 510(k) Clearance for STITCH UHMWPE High-Strength Surgical Sutures

• Summary: GMReis obtained FDA 510(k) clearance for its STITCH portfolio of ultra-high-molecular-weight polyethylene (UHMWPE) non-absorbable surgical sutures and braided sleeves. Specifically developed for sports medicine, extremity reconstruction, and tendon-to-bone reattachment, STITCH provides high tensile strength, knot security, and reduced tissue abrasion for integration with suture anchors and flexible orthopaedic fixation systems.
• Key Details:
  • Device/System Name: STITCH™ UHMWPE Surgical Suture & Braided Sleeve System
  • Status: FDA 510(k) Cleared (August 25–26, 2026)
  • Clinical Significance: Enhances mechanical fixation strength in rotator cuff repair, labral reconstruction, and ligamentous reattachment, reducing elongation and anchor pullout risks under high athletic loads.
• Original Source: GMReis FDA 510(k) Clearance Report — Orthoworld

Spine Health Policy & Reimbursement

DeGen Medical — Statement on CMS FY2027 Inpatient Classification for Patient-Specific Lumbar Fusion

• Summary: DeGen Medical released an industry statement addressing the finalized CMS Inpatient Prospective Payment System (IPPS) classifications for fiscal year 2027. The updated coding frameworks establish explicit reimbursement pathways for patient-specific, 3D-printed titanium implants used in complex adult spinal deformity and revision fusion, providing financial predictability for hospital adoption of personalized spinal implants.
• Key Details:
  • Device/System Name: Patient-Specific 3D-Printed Titanium Lumbar Implants
  • Status: Regulatory & Health Policy Review
  • Clinical Significance: Removes hospital reimbursement barriers for custom 3D-printed interbody and fixation constructs, expanding patient access in complex reconstructive spine cases.
• Original Source: DeGen Medical CMS Policy Statement — OrthoSpineNews

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)

We’re looking for the next intern to join the Lead Change Podcast and help tell the stories of leaders shaping medicine and orthopaedic surgery.

Hosted by Dr. Mary K. Mulcahey, the Lead Change Podcast features conversations with leaders across medicine, orthopaedics, academia, and professional societies - exploring leadership, mentorship, career development, and the experiences that shape meaningful change.

Ideal Candidate: A first- or second-year medical student, or a medical student currently taking a gap year.

Roles
• Podcast video editing and production
• Social media content and newsletter creation
• Develop strategies to grow the podcast’s reach and engagement
• Help promote and highlight upcoming episodes and guests

Commitment
~5 hours/week

What You’ll Gain

• Direct mentorship in orthopaedics - build meaningful relationships with faculty who can support your research, career development, and journey toward residency

• Network with leaders in orthopaedic surgery - connect with current and former society presidents, department chairs, program directors, and other influential leaders featured on the podcast

• Strengthen your residency portfolio through meaningful involvement in leadership, research, academic outreach, and professional service

• Research and presentation opportunities with the potential to contribute to projects presented at major national and international meetings, including AAOS, RJOS, SICOT, and many more...

• Early exposure to the orthopaedic community - learn directly from surgeons about leadership, mentorship, career development, and navigating a career in orthopaedics

• Develop skills that set you apart in leadership, communication, digital media, strategy, and academic collaboration

Stipend
$100/month

Interested in carrying the torch? 

The Orthopedic Research Scholar opportunity is a one-year position that gives an outstanding medical student the opportunity to be part of globally recognized research in the Pediatric Orthopedic Department at the Nemours Children’s Hospital.

This fellowship provides the medical student with all the tools necessary to be successful in the development and execution of meaningful pediatric orthopedic research projects during the year, with a view to presentation at national meetings and eventual publication. Through this program, the candidate will have access to substantial research resources including statistical support, research methods instruction (through our integrated research education seminar series), IRB-support, clinical databases, and more.

The Department of Orthopaedic Surgery at Wake Forest University School of Medicine offers a 2-year Orthopaedic Physician Scientist Training Program. The program is a two year postdoctoral experience of mentored and protected basic science research time prior to clinical residency. The goal of the program is to provide applicants with a foundation in basic science research and the necessary knowledge and skills to pursue a career in academic Orthopaedic Surgery. In addition, Physician Scientists have the opportunity to seek further education by pursuing a Doctor of Philosophy degree in the Wake Forest Graduate School of Arts and Sciences.

Physician Scientists spend two years in the Orthopaedic Research Laboratories to pursue basic science in their respective field of interest within Orthopaedic Surgery. During this time, they are mentored by experienced basic science researchers and clinical collaborators. The protected research time allows the physician scientist to design studies and prepare competitive research grants and have access to collaborating departments (Biomedical Engineering, Regenerative Medicine, Neuroscience, Physiology and Pharmacology, Comprehensive Cancer Center, Biostatistics and Population Medicine, Translational Sciences).

During the two year program, Physician Scientists do not have any call obligations; however, they participate in the core educational curriculum of the 5-year residency including educational conferences, Orthopaedic Grand Rounds and subspecialty journal clubs. In addition, physician scientists may serve as medical student facilitators, and mentor postdoctoral fellows, medical students, and visiting international medical students and collaborate with fellow residents in research projects.

The Physician Scientist Program is a 2-year postdoctoral experience separate from Wake Forest's 5-year Orthopaedic Residency Program.  In order to comply with ACGME (Accreditation Council for Graduate Medical Education) and NRMP (National Resident Matching Program) guidelines, the Physician Scientist Program is not directly linked to the 5-year Orthopaedic Residency Program.  Therefore, if you wish to pursue your residency training at Wake Forest Baptist Medical Center, you must complete the standard process which includes, in part, an ERAS residency application, registration for the match, and adherence to the ACGME and NRMP guidelines.

Although the physician scientist program and the residency are not linked; they are synergistic and application to the residency is encouraged and supported within the NMRP guidelines.  Successful completion of the physician scientist program is factored significantly by the selection committee.

Application Process (Deadline September 23rd, 2026)

Candidates are asked to apply via the Electronic Residency Application Service (ERAS). There is no separate program code for the Physician Scientist Program. Candidates are asked to send a short letter expressing their interest to Kerry A. Danelson, PhD, at Kerry.Danelson@wfusm.edu . Once these are received, their file will receive consideration for both the traditional (5 year) residency program and the Physician Scientist Fellowship Program.  All candidates must be U.S. Medical School Graduates or have received ECFMG certification.